Company intelligence / Profile preview

Ixaka

London, United Kingdomixaka.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Ixaka develops proprietary cell and gene therapy platforms aimed at harnessing the body’s natural healing powers. Its lead programs include a preclinical CD19-targeting CAR-T therapy for hematologic cancers. The company previously advanced a cell therapy for chronic limb-threatening ischemia but has since discontinued it. Ixaka’s technologies are designed to enhance therapeutic efficacy by targeting or modifying cells directly at disease sites. The company has raised over £40 million from shareholders to accelerate its development efforts across oncology and other serious diseases with unmet needs

Therapeutic areas: OtherHematologyCardiovascular
Modalities: Concentrated multi-cell therapies (MCTs)Targeted nanoparticle therapeutics (TNPs)CAR-T cell therapy
Industry: Biotech

Beyond the preview

Go deeper on Ixaka.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ixaka.